AgomAb Therapeutics NV

AgomAb Therapeutics NV에 대해 보유한 최신 분기

기업이 직접 제출한 6-K에서 가져왔습니다.

경영진의 발언

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

AgomAb Therapeutics NV은(는) 무엇을 하는 기업인가

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

발표 자료 말미에 실린 기업 자신의 소개글입니다.